Intl. Congress form | International Congress Report | International Congress Report For Faculty | Baltimore USA International Conference on Vaccines Research & Development November 02 - 04, 2015

Home

Code : 9345-350757 Created Date : Monday, January 4, 2016 Update Date : Monday, January 4, 2016 Visit : 1846

Baltimore USA International Conference on Vaccines Research & Development November 02 - 04, 2015

The report of Baltimore USA International Conference on Vaccines Research & Development November 02 - 04, 2015 by Dr. Afshineh Latifynia

Application Code :

306-0215-0143

Created Date : Wednesday, November 25, 2015 14:39:24Update Date : Sunday, December 27, 2015 14:02:23
IP Address : 194.225.51.101Submit Date : Sunday, December 27, 2015 14:03:09Email : alatifynia@tums.ac.ir

Personal Information

Name :	Afshineh
Surname :	Latifynia
School/Research center :	School of Medicine
If you choose other, please name your Research center :
Position :	instructor
Tel :	+98-21-22565383

Information of Congress

Title of the Congress :	Baltimore USA International Conference on Vaccines Research & Development November 02 - 04, 2015
Title of your Abstract :	Cytokine assay (ILs 4, 10, 12, 17, 23, IFN-γ), CD8+& CD4+ compare to expansion of spleen white pulp size in pre challenge Balb/c mice vaccinated by the Leishmania major new vaccine.
Destination Country :	United States
From :	Monday, November 2, 2015
To :	Wednesday, November 4, 2015
Abstract(Please copy/paste the abstract send to the congress) :	Cytokine assay (ILs 4, 10, 12, 17, 23, IFN-γ), CD8+& CD4+ in pre challenge Balb/c mice vaccinated by the Leishmania major new vaccine. Latifynia Afshineh ¹,², Gharagozlou Mohammad Javad³, Niknam Mohammad Hossein ¹, Farashi Bonab Samad ¹, Ansaripour Bita¹, Gheflati Zahra¹, Hajjaran Homa 4 , Khansari Nematollah¹ ¹Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran ²Research Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran ³Department of Pathobiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran 4Department of Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Corresponding author: Latifynia Afshineh, Dept. of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Tel:982166439463; E-mail: alatifynia@sina.tums.ac.ir Abstract: Objective: Leishmaniasis, a zoonotic protozoan disease is common in the south and Central America, Asia and Africa continents where phlebotomus mosquito species transmit the disease between susceptible species. The companion animals and wild species can act as reservoir and maintain the parasite in the environment. This parasite is seen as amastigote form in vertebrate animals and promastigote form in the insects. Leishmaniasis affects about 12 million people from 88 countries and creates a complex and unpleasant disease that is long lasting, hard to treat and sometimes a life threatening disease that is known as visceral leishmaniasis. For this reason, development of an effective and a safe vaccine that protects the susceptible species is necessary. According to our previous finding of the author related to the new formulated provisional vaccine, it seems that a complex humoral and cellular response followed by vaccination to be involved, which required further investigation. Methods: In the present project, we had six vaccinated groups received either 100 or 200 microgram/0.1ml L.major cocktail antigen, each of them also received Leishmania + BCG (LB), Leishmania + Teucrium (LT), or Leishmania + BCG + Teucrium (LBT) groups, and also one control group was considered. After vaccination and booster dose, CD4+ and CD8+ T cells profile of the lymphoid tissues and serum levels of immune effector cytokines including ILs-4, 10, 12, 17, 23, IFN-gamma were evaluated and the findings were analyzed statistically. Results: Considering the six vaccinated groups compared together and normal group : number and size of pulps, percent of spleen weight /mouse weight, interferon gamma with mean of white pulp size, CD4+ with CD3+,IL- 23 with IFN-γ have had significant differences. And also without considering two injection doses, and considering to three injection groups: IL-10, lL-23, IL-12, CD25+, CD3+&CD4+ have had significant differences which may indicate a satisfactory immune response to the new formulated L.major antigen as a provisional vaccine.
Keywords of your Abstract :	Keywords: Leishmania major, Vaccine, Cytokines, Th1 &Th2, CD4+&CD8+, Balb/c mice.
Acceptance Letter :	http://gsia.tums.ac.ir/images/UserFiles/16240/Forms/306/Afshineh Latifynia invitation letter_1.pdf
The presentation :	Oral
The Cover of Abstract book :	http://gsia.tums.ac.ir/images/UserFiles/16240/Forms/306/روي_جلد_كتابچه.pdf
Published abstract in the abstract book with the related code :	http://gsia.tums.ac.ir/images/UserFiles/16240/Forms/306/خلاصه_مقاله.pdf
Where has your abstract been indexed? :	other
If you choose other, please name :	google scholar

The Congress Reporting Form

How many volunteers were present at the Congress? :	Almost 160 volunteers.
Delegates from which countries presented in the congress? :	USA,Canada,Swetzerland,Spain,Germany,.....and Iran.
Were the delegates of any other organizations present in the congress? :	Yes
If yes, please write the names of the organizations in the box :	NIH,CEO,Profectus Biosciences, USA, AERAS, USA,NIAID, NIH, Sano Pasteur,...........Cellular Technology Limited (CTL),LumaCyte,National Cancer Institute USA,
What were the responses to your talking points? Were specific questions or concerns raised? :	Chair of my lecture tell to all delegates: "Our works have technology, but Iranian works had strength and high potential".
If you met staff members, please list their full names & positions. :	only in conference
Please inform us if there are any follow up actions we need to talk with the members of the congress :	Thank you very much of your attention .I invited and have two oral lectures as corresponding author in this important congress one lecture present by me as first author and second present by Dr. Mohammad Javad Gharagozlou as first author. It was a very scientific and regular Congress. I was invited lecturer and was treated very respectfully towards us and our oral lectures. Chair of my lecture tell to all delegates: "Our works have technology, but Iranian works had strength and high potential". Abstracts of My two lectures published in abstract book” new era in vaccine discovery”. I would like to inform you that, I invited as speaker to another vaccine congresses 2015 & 2016. I hope can participate to some of these important congresses and present our results excellent lecture previously, also. I request that help me that I could ready partial of future examination to present these important congresses. It is important that they are very expensive for us, especially more for USA travel.
Your experiences about the travel processes(Providing ticket, accommodation,...) :	It is difficult and very expensive for us.
Please give a briefing of your own observations and outcomes of the congress: :	Thank you very much of your attention .I invited and have two oral lectures as corresponding author in this important congress one lecture present by me as first author and second present by Dr. Mohammad Javad Gharagozlou as first author. It was a very scientific and regular Congress. I was invited lecturer and was treated very respectfully towards us and our oral lectures. Chair of my lecture tell to all delegates: "Our works have technology, but Iranian works had strength and high potential". Abstracts of my two lectures published in abstract book” new era in vaccine discovery”. More than of 160 volunteers were present at the Congress from following countries USA, Canada, Switzerland, Spain, Germany,.....and Iran, presented in the congress. Almost 70-75% delegates were of USA (NIAID, NIH, USA, CEO, Profectus Biosciences, USA, AERAS, USA, NIAID, NIH, USA and others. Bronze Sponsors for this important congress were: Sanofi Pasteur, InDeVR (Inspired life Sciece Tecnology), and, Supporting Sponsors for this important congress were: Lumacyte, AERAS, CEO (Cellular Technology Ltd). I would like to inform you that invited as speaker to other vaccine congresses 2015 & 2016. I hope can participate to some of these important congresses and present our results excellent lecture previously, also. I request that help me that I could ready partial of future examination to present these important congresses. It is important that they are very expensive for us, especially more for USA travel.

Home Printer Friendly Tell a Friend Comment

Your Comments :